RT Journal Article
SR Electronic
T1 Transcatheter closure of ventricular septal defects by exclusive transvenous antegrade cannulation from the right ventricle
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.28.24308078
DO 10.1101/2024.05.28.24308078
A1 Sagar, Pramod
A1 Thejaswi, Puthiyedath
A1 Garg, Ishita
A1 Sivakumar, Kothandam
YR 2024
UL http://medrxiv.org/content/early/2024/05/29/2024.05.28.24308078.abstract
AB Background Transcatheter closure(TCC) of perimembranous ventricular septal defects(PM-VSD) and intraconal defects routinely involves either arteriovenous loop formation or direct retrograde device deployment from its left ventricular(LV) end. An arterial access is always taken for a left ventriculogram. Direct antegrade cannulation of the defect from the right ventricle for TCC avoids complications associated with femoral arterial access and arteriovenous loop formation.Methods Feasibility of elective antegrade cannulation for TCC of PM-VSD, intraconal VSD and postoperative residual VSD was retrospectively studied over five years from 2019-2023. Echocardiographic VSD measurements guided the device selection rather than left ventriculographic measurements. Predictors for successful antegrade cannulation and transvenous device deployment were analyzed.Results Antegrade cannulation was electively attempted in 116/163(71%) TCC VSD closure procedures. The proportion of cases where this antegrade cannulation was electively employed progressively increased from 26% of interventions performed in 2019 to 93% in 2023. The median age of the study cohort that included 24 infants was 55 months (range 1-636 months) and the indexed VSD size was 9.2 mm/m2 (range 1.7-43.3 mm/m2). Two-thirds of patients had varying degrees of pulmonary arterial hypertension. Antegrade cannulation was successful in 97(83.6%) patients. In the remaining 19 patients, retrograde cannulation from LV aided TCC. There were no deaths or need for pacemaker implantation. Overall procedural success of TCC in this cohort was 99.1%.Device embolization with tricuspid chordal tear led to procedural failure in one patient. Four other device embolizations were managed successfully by transcatheter retrieval and closure with an upsized device. Young age, small body size, large VSD size were significantly associated with successful antegrade cannulation.Conclusions Antegrade cannulation and TCC was feasible in majority of the procedures, especially in small patients and large defects. This strategy simplified the procedure without arterial access and might replace the routine retrograde device delivery and AV loop formation.Graphical abstract An exclusive transvenous antegrade defect cannulation from the right ventricle would avoid complications due to arterial access and arteriovenous railroad formation, simplify procedure and allow assessment of aortic valve before device release.What is already knownTranscatheter closure of ventricular septal defects around the membranous septum is increasingly performed using soft occluder devices with results comparable to surgery.Conventional approach involves a retrograde trans-arterial cannulation of the defect or arteriovenous loop formation.What this study addsTransvenous antegrade cannulation and device deployment is an alternative attractive technique.As this avoids arterial access, additional hardware needed for arteriovenous loop formation and allows intraprocedural monitoring of aortic valve, this might replace the conventional techniques in future.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis retrospective study did not require a trial IDFunding StatementNo funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board, Madras Medical Mission, IndiaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data will be available on a reasonable request to the corresponding authorTCCTranscatheter closurePM-VSDPerimembranous ventricular septal defectVSDventricular septal defectAVarteriovenousLVleft ventricleRVright ventricleNCCnon coronary cuspRCCright coronary cuspARaortic regurgitationPApulmonary arteryADOAmplatzer duct occluder KonarMFKonar multifunction occluder